Skip to main content
LGND
NASDAQ Life Sciences

Ligand Pharmaceuticals Reports Strong Q1 2026 Results with Significant Operating Income Turnaround and Royalty Growth

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$221.41
Mkt Cap
$4.437B
52W Low
$98.89
52W High
$247.38
52W Position info
124% above low
Off High info
10% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

LGND has more than doubled off its 52-week low of $98.89.

Summary

Ligand Pharmaceuticals reported a substantial improvement in its first-quarter 2026 financial performance, driven by robust royalty revenue growth and a significant swing to operating income, while also providing updates on key pipeline assets and recent strategic transactions.


Key Events · Earnings and Guidance · LGND

  • Strong Financial Performance

    Q1 2026 total revenue and income increased by 14% to $51.7 million, with royalties surging 56% to $43.0 million. The company achieved an operating income of $17.4 million, a significant turnaround from a $36.2 million operating loss in Q1 2025.

  • Reduced Net Loss

    The net loss for Q1 2026 significantly narrowed to $13.3 million, compared to a $42.5 million net loss in the prior year, primarily due to the improved operating performance.

  • Increased Liquidity

    Cash, cash equivalents, and short-term investments rose by $45.9 million to $779.4 million as of March 31, 2026, with net cash from operating activities turning positive at $48.7 million.

  • Key Royalty Asset Updates

    Positive developments include FDA approval for Filspari in FSGS, Breakthrough Device Designation for AVIM Therapy, and expanded Tzield indication for younger patients.


Analysis · LGND · Life Sciences

This 10-Q provides a comprehensive overview of Ligand's strong first-quarter performance, confirming the positive trends previously hinted at in the recent 8-K. The significant swing to operating income and reduced net loss demonstrate improved operational efficiency and the growing strength of its royalty portfolio. The detailed updates on multiple partnered programs, including new FDA approvals and designations, underscore the company's strategic focus on high-value medicines. While the XOMA acquisition and Viking termination were previously announced, their inclusion here provides a consolidated view of recent strategic moves. Investors should view the improved financial health and pipeline progress as positive indicators for future growth, despite the potential for future dilution from the ATM program which has not yet seen sales.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LGND was trading at $221.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.4B. The 52-week trading range was $98.89 to $247.38. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LGND - Latest Insights

LGND
Oct 30, 2026, 4:47 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $324.00
Real-time Price: $301.52 info
Change: -$22.48 (-7%) info
Market Cap: $6.031B info
LGND
Oct 29, 2026, 3:12 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $316.21
Real-time Price: $301.52 info
Change: -$14.69 (-5%) info
Market Cap: $6.031B info
LGND
Oct 29, 2026, 7:14 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $311.87
Real-time Price: $301.52 info
Change: -$10.35 (-3%) info
Market Cap: $6.031B info
LGND
Oct 29, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $311.87
Real-time Price: $301.52 info
Change: -$10.35 (-3%) info
Market Cap: $6.031B info
LGND
Sep 24, 2026, 7:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $298.41
Real-time Price: $301.52 info
Change: +$3.11 (+1%) info
Market Cap: $6.031B info